

Abbreviated Unaudited Accounts

for the Year Ended 30 June 2015

for

Neuropharm Limited

**Contents of the Abbreviated Accounts
for the Year Ended 30 June 2015**

	Page
Company Information	1
Abbreviated Balance Sheet	2
Notes to the Abbreviated Accounts	4
Chartered Certified Accountants' Report	5

Neuropharm Limited

Company Information
for the Year Ended 30 June 2015

DIRECTOR: Dr P Herscu

SECRETARY: Dr P Herscu

REGISTERED OFFICE: Beechey House
87 Church Street
Crowthorne
Berkshire
RG45 7AW

REGISTERED NUMBER: 05510905 (England and Wales)

ACCOUNTANTS: PKB UK LLP
Chartered Certified Accountants
Beechey House
87 Church Street
Crowthorne
Berkshire
RG45 7AW

Abbreviated Balance Sheet
30 June 2015

	Notes	30.6.15 £	30.6.14 £
FIXED ASSETS			
Intangible assets	2	-	-
CURRENT ASSETS			
Debtors		10	10
CREDITORS			
Amounts falling due within one year		<u>1,333</u>	<u>1,333</u>
NET CURRENT LIABILITIES		<u>(1,323)</u>	<u>(1,323)</u>
TOTAL ASSETS LESS CURRENT LIABILITIES		<u>(1,323)</u>	<u>(1,323)</u>
CAPITAL AND RESERVES			
Called up share capital	3	789	789
Share premium		909,961	909,961
Profit and loss account		<u>(912,073)</u>	<u>(912,073)</u>
SHAREHOLDERS' FUNDS		<u>(1,323)</u>	<u>(1,323)</u>

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 30 June 2015.

The members have not required the company to obtain an audit of its financial statements for the year ended 30 June 2015 in accordance with Section 476 of the Companies Act 2006.

The director acknowledges his responsibilities for:

- (a) ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.
- (b)

Abbreviated Balance Sheet - continued
30 June 2015

The abbreviated accounts have been prepared in accordance with the special provisions of Part 15 of the Companies Act 2006 relating to small companies.

The financial statements were approved by the director on 29 March 2016 and were signed by:

Dr P Herscu - Director

Notes to the Abbreviated Accounts
for the Year Ended 30 June 2015

1. ACCOUNTING POLICIES

Accounting convention

The financial statements have been prepared under the historical cost convention and in accordance with the Financial Reporting Standard for Smaller Entities (effective April 2008).

The company was dormant throughout the year ended 30 June 2015. However, reference to information relating to the year ended 30 June 2014 has been made where appropriate.

2. INTANGIBLE FIXED ASSETS

	Total £
COST	
At 1 July 2014	50,000
Disposals	(50,000)
At 30 June 2015	-
AMORTISATION	
At 1 July 2014	50,000
Eliminated on disposal	(50,000)
At 30 June 2015	-
NET BOOK VALUE	
At 30 June 2015	-
At 30 June 2014	-

3. CALLED UP SHARE CAPITAL

Allotted, issued and fully paid:

Number:	Class:	Nominal value:	30.6.15 £	30.6.14 £
789	Ordinary	£1	<u>789</u>	<u>789</u>

The ordinary shares have full voting rights.

**Chartered Certified Accountants' Report to the Director
on the Unaudited Financial Statements of
Neuropharm Limited**

The following reproduces the text of the report prepared for the director in respect of the company's annual unaudited financial statements, from which the unaudited abbreviated accounts (set out on pages two to four) have been prepared.

In order to assist you to fulfil your duties under the Companies Act 2006, we have prepared for your approval the financial statements of Neuropharm Limited for the year ended 30 June 2015 which comprise the Profit and Loss Account, the Balance Sheet, and the related notes from the company's accounting records and from information and explanations you have given us.

As a practising member firm of the Association of Chartered Certified Accountants, we are subject to its ethical and other professional requirements which are detailed at <http://rulebook.accaglobal.com>.

This report is made solely to the director of Neuropharm Limited in accordance with our terms of engagement. Our work has been undertaken solely to prepare for your approval the financial statements of Neuropharm Limited and state those matters that we have agreed to state to the director of Neuropharm Limited in this report in accordance with the requirements of the Association of Chartered Certified Accountants as detailed at <http://www.accaglobal.com/factsheet163>. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the company and its director for our work or for this report.

It is your duty to ensure that Neuropharm Limited has kept adequate accounting records and to prepare statutory financial statements that give a true and fair view of the assets, liabilities, financial position and profit of Neuropharm Limited. You consider that Neuropharm Limited is exempt from the statutory audit requirement for the year.

We have not been instructed to carry out an audit or a review of the financial statements of Neuropharm Limited. For this reason, we have not verified the accuracy or completeness of the accounting records or information and explanations you have given to us and we do not, therefore, express any opinion on the statutory financial statements.

PKB UK LLP
Chartered Certified Accountants
Beechey House
87 Church Street
Crowthorne
Berkshire
RG45 7AW

30 March 2016

This document was delivered using electronic communications and authenticated in accordance with the registrar's rules relating to electronic form, authentication and manner of delivery under section 1072 of the Companies Act 2006.